Chemical Financing Activity Mixed (ICIS Chemical Business August 7 – August 13, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of financing trends in the first half of 2026 and the future outlook in 2026.
A Survey of Senior Chemical Industry Executives
Young & Partners shares with our analysis of the current and future sentiment and outlook of chemical industry executives in 2026.
Chemical M&A Surges (ICIS Chemical Business July 31, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
Cautious Momentum: Biopharma Review and Outlook (Pharmaceutical Executive March 2026)
Young & Partners shares with Pharmaceutical Executive on our analysis of M&A trends for Pharmaceuticals and Biotech in 2025 and the future outlook of M&A in 2026.
Chemicals M&A To See Upturn in 2026 (Chemical Week Feb 2 – Feb 9, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
The Good, The Bad, and the Ugly (ICIS Chemical Business Jan 30 – Feb 5, 2026)
Young & Partners reports on our analysis of chemical stock market and financing trends for 2025 and the future outlook in 2026.
Signs of Revival in Chemical M&A (ICIS Chemical Business Jan 23 – Jan 29, 2026)
Young & Partners reports on our analysis of M&A markets for 2025 and the future outlook for Chemical M&A.
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Navigating Divergent Currents – Biopharma Review and Outlook (Pharmaceutical Executive, August 2025)
Young & Partners shares proprietary analysis of the M&A, stock market, and funding environment in Biotech and Pharma and the outlook for 2025.